Q2 EPS Estimate for Daré Bioscience Lifted by Analyst

Daré Bioscience, Inc. (NASDAQ:DARE) – Equities researchers at Brookline Capital Management upped their Q2 2025 earnings per share estimates for shares of Daré Bioscience in a research note issued on Tuesday, May 13th. Brookline Capital Management analyst K. Dolliver now expects that the biotechnology company will earn ($0.48) per share for the quarter, up from their prior forecast of ($0.62). The consensus estimate for Daré Bioscience’s current full-year earnings is ($0.49) per share. Brookline Capital Management also issued estimates for Daré Bioscience’s Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.57) EPS and FY2025 earnings at ($2.03) EPS.

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Daré Bioscience in a research note on Tuesday, April 1st.

Daré Bioscience Stock Down 0.3%

DARE stock opened at $2.88 on Friday. The company’s 50-day moving average price is $2.92 and its two-hundred day moving average price is $3.18. The firm has a market cap of $25.49 million, a P/E ratio of -4.88 and a beta of 1.20. Daré Bioscience has a 12 month low of $2.67 and a 12 month high of $7.56.

Daré Bioscience (NASDAQ:DARE) last issued its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.13. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.60 million. During the same quarter last year, the firm posted ($0.84) earnings per share.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of DARE. Geode Capital Management LLC raised its holdings in Daré Bioscience by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock worth $289,000 after purchasing an additional 3,593 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Daré Bioscience by 6.7% during the fourth quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock worth $214,000 after buying an additional 4,300 shares during the period. AMH Equity Ltd raised its stake in Daré Bioscience by 9.5% during the first quarter. AMH Equity Ltd now owns 164,302 shares of the biotechnology company’s stock worth $475,000 after buying an additional 14,302 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in Daré Bioscience in the fourth quarter valued at $52,000. 6.70% of the stock is owned by institutional investors and hedge funds.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.